最新消息 - 昱厚生技股份有限公司

January 1, 2019

【中時】昱厚生技噴鼻流感疫苗二期臨床試驗結果超乎預期

Press

December 19, 2018

Phase II Clinical Trial Results Demonstrate the Company's Intranasal Influenza Vaccine AD07030 Exhibits No Safety or Tolerability Concerns and Enhances Both Serum and Mucosal Immune Responses, Successfully Meeting Trial Objectives.

Updates

November 5, 2018

Received TFDA Approval to Conduct Phase Ib/IIa Clinical Trial: "A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of AD17002-AI in Subjects with House Dust Mite-Induced Allergic Rhinitis."

Updates

September 1, 2018

The Company Submits Phase Ib/IIa Clinical Trial Application to the Taiwan FDA for LTh(αΚ) for House Dust Mite-Induced Allergic Rhinitis, with Clearance Expected in Q4 2018.

Updates

January 12, 2018

【DJ新視界】昱厚噴鼻疫苗之佐劑可加速療效

Press

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

【中時】昱厚生技噴鼻流感疫苗二期臨床試驗結果超乎預期

Phase II Clinical Trial Results Demonstrate the Company's Intranasal Influenza Vaccine AD07030 Exhibits No Safety or Tolerability Concerns and Enhances Both Serum and Mucosal Immune Responses, Successfully Meeting Trial Objectives.

Received TFDA Approval to Conduct Phase Ib/IIa Clinical Trial: "A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of AD17002-AI in Subjects with House Dust Mite-Induced Allergic Rhinitis."

The Company Submits Phase Ib/IIa Clinical Trial Application to the Taiwan FDA for LTh(αΚ) for House Dust Mite-Induced Allergic Rhinitis, with Clearance Expected in Q4 2018.

【DJ新視界】昱厚噴鼻疫苗之佐劑可加速療效

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

【中時】昱厚生技 噴鼻流感疫苗二期臨床試驗結果超乎預期

Phase II Clinical Trial Results Demonstrate the Company's Intranasal Influenza Vaccine AD07030 Exhibits No Safety or Tolerability Concerns and Enhances Both Serum and Mucosal Immune Responses, Successfully Meeting Trial Objectives.

Received TFDA Approval to Conduct Phase Ib/IIa Clinical Trial: "A Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of AD17002-AI in Subjects with House Dust Mite-Induced Allergic Rhinitis."

The Company Submits Phase Ib/IIa Clinical Trial Application to the Taiwan FDA for LTh(αΚ) for House Dust Mite-Induced Allergic Rhinitis, with Clearance Expected in Q4 2018.

【DJ新視界】昱厚噴鼻疫苗之佐劑 可加速療效

【中時】昱厚生技噴鼻流感疫苗二期臨床試驗結果超乎預期

【DJ新視界】昱厚噴鼻疫苗之佐劑可加速療效